Drugs / Optaflu(®)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00579345 | Oct 2007 → Jun 2008 | influenza | Novartis | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Optaflu() | “Adult and elderly subjects previously immunized with cell culture-derived (CCIV; Optaflu(®)) or egg-derived (TIV; Agrippal(®)) trivalent influenza vaccines” PMID 22418809 ↗ May 2012 |
| Known as | CCIV | “Adult and elderly subjects previously immunized with cell culture-derived (CCIV; Optaflu(®)) or egg-derived (TIV; Agrippal(®)) trivalent influenza vaccines” PMID 22418809 ↗ May 2012 |
| Known as | cTIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00579345 ↗ |
| Modality | Vaccine | “cell cultured trivalent influenza vaccine (cTIV) vaccine” NCT00579345 ↗ |
| Route | Intramuscular | “administered as 0.5 mL single dose in the deltoid muscle” NCT00579345 ↗ |